Helsinki-based Gosta Labs has secured €7.5 million in Seed funding to expand its AI operating system for oncology teams. The technology reportedly reduces documentation time by over two-thirds per patient visit, freeing oncologists from administrative burdens. This comes as global cancer cases are p
New studies show multimodal AI can predict cancer treatment outcomes better than current methods. The technology combines medical images, clinical notes and tumor biology to spot patterns humans miss. Several companies are already bringing these tools closer to real-world use.
A groundbreaking study reveals how machine learning can overcome traditional limitations in skin cancer detection. The research shows dramatic differences in diagnosis age and risk factors across ethnic groups.
Researchers have created a breakthrough gene-editing platform that reprograms cancer cells’ genetic tolerance to treatment. The technology transforms tumors into immunotherapy-responsive targets while creating durable immune memory against recurrence.
Scientists have developed a novel nanoplatform that uses CRISPR gene editing to transform how cancers respond to immunotherapy, according to reports published in Nature Biomedical Engineering. The technology targets haem oxygenase-1 (HO-1), a key enzyme that tumors use to develop resistance to reactive oxygen species, which are crucial components of many cancer treatments.
Decoding Cancer’s Shape-Shifting Abilities Through Chromatin Architecture Groundbreaking research published in Nature Communications has revealed a previously unknown mechanism behind…
Elevance Health announced third quarter net income of $1.18 billion despite increasing medical expenses across its health plans. The health insurer’s revenue grew 12.4% to $50.7 billion, driven by premium yields and Medicare Advantage growth.
Elevance Health, the nation’s second-largest health insurer, reportedly achieved $1.18 billion in net income during the third quarter, representing a 17.8% increase compared to the same period last year, according to the company’s earnings report. The performance comes amid what analysts describe as ongoing cost pressures in the healthcare sector, particularly within government-subsidized insurance programs.
The Dawn of Bionic Vision Restoration In what medical researchers are calling a watershed moment for ophthalmology, a miniature silicon…
Zika’s Hidden Legacy in Maternal-Child Immunity The 2015 Zika outbreak in Brazil revealed more than just the virus’s devastating potential—it…
Breakthrough in Medical Diagnostics In a significant advancement for medical technology, machine learning algorithms have demonstrated superior capability in identifying…
Researchers have developed a deep learning system that significantly improves the detection and classification of rare cancer cells in liquid biopsy samples. The technology demonstrates enhanced robustness to technical variations and superior performance across multiple analytical tasks compared to traditional methods.
Researchers have developed a sophisticated deep learning system that reportedly enables comprehensive phenotypic analysis of individual cells in whole slide imaging for liquid biopsy applications, according to recent study findings. The framework, which combines segmentation and feature extraction capabilities, demonstrates significant improvements in identifying and classifying rare tumor-associated cells that are critical for cancer diagnosis and monitoring.
